Table 2.
Baseline demographic, clinical, and transplantation characteristics
| Calcitriol n = 40 |
Placebo n = 40 |
|
|---|---|---|
| Gender | ||
| Male | 25 (62.5%) | 29 (72.5%) |
| Female | 15 (37.5%) | 11 (27.5%) |
| Age (y) | ||
| Mean ± SD | 47.53 ± 13.49 | 46.93 ± 14.39 |
| Median (range) | 50.0 (21.0–65.0) | 50.0 (18.0–68.0) |
| Body mass index (kg/m2) | ||
| Mean ± SD | 26.75 ± 4.49 | 27.07 ± 4.25 |
| Background conditions | ||
| Diabetes | 1 (2.5%) | 2 (5.0%) |
| Hepatitis B | 1 (2.5%) | 1 (2.5%) |
| Cardiovascular disease | 2 (5.0%) | 1 (2.5%) |
| Thyroid disease | 0 (0.0%) | 1 (2.5%) |
| Hematologic malignancy | ||
| Multiple myeloma | 22 (55.0%) | 20 (50.0%) |
| Hodgkin lymphoma | 10 (25.0%) | 10 (25.0%) |
| Non-Hodgkin lymphoma | 8 (20.0%) | 10 (25.0%) |
| Conditioning regimen | ||
| MLP | 22 (55.0%) | 20 (50.0%) |
| VP16 + CYT + CBP + MLP | 18 (45.0%) | 20 (50.0%) |
| Cycles of chemotherapy before transplantation | ||
| Median (range) | 8.0 (2.0–24.0) | 8.0 (3.0–23.0) |
| Cycles of radiotherapy before transplantation | ||
| Median (range) | 0.0 (0.0–24.0) | 0.0 (0.0–65.0) |
| Time from diagnosis to transplantation (month) | ||
| Median (range) | 19.50 (7.0–108.0) | 19.50 (5.0–156.0) |
| Viability of the transplant product (%) | ||
| Mean ± SD | 94.41 ± 4.78 | 94.56 ± 4.94 |
| Volume of the transplant product (ml) | ||
| Median (range) | 390.0 (160.0–793.0) | 432.0 (300.0–953.0) |
| Dose of CD34+ cells (×106/kg) | ||
| Median (range) | 1.89 (0.21–22.50) | 1.38 (0.45–15.10) |
| Dose of TNC (×108/kg) | ||
| Median (range) | 13.06 (4.98–34.83) | 12.20 (3.88–34.72) |
| Dose of MNC (×108/kg) | ||
| Median (range) | 10.25 (5.09–19.30) | 9.81 (4.0–17.01) |
Abbreviations: CBP carboplatin, CYT cytarabine, MLP melphalan, MNC mononuclear cells, SD standard deviation, TNC total nucleated cells, VP16 etoposide